MetaADEDB 2.0 @ LMMD
dipropylacetamide
(OMOMUFTZPTXCHP-UHFFFAOYSA-N)
Structure
SMILES
CCCC(C(=O)N)CCC
Type(s)
Experimental
ATC code(s)
N03AG02
Molecular Formula:
C8H17NO
Molecular Weight:
143.227
Log P:
2.3884
Hydrogen Bond Acceptor:
2
Hydrogen Bond Donor:
1
TPSA:
43.09
CAS Number(s):
2430-27-5
Synonym(s)
1.
dipropylacetamide
2.
Depamide
3.
valproic acid amide
4.
valpromide
External Link(s)
MeSHC004651
PubChem Compound71113
ChEBI74562
CHEMBLCHEMBL93836
DrugBankDB04165
DrugCentral2804
KEGGdr:D02766
ZINC2238
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1AbuseOFFSIDES
2Acute Coronary SyndromeOFFSIDES
3Acute prerenal failureOFFSIDES
4Altered state of consciousnessOFFSIDES
5AmphetaminesOFFSIDES
6AngioedemaOFFSIDES
7AnhedoniaOFFSIDES
8Antidepressant drug level increasedOFFSIDES
9ApathyOFFSIDES
10Bacterial test positiveOFFSIDES
11Biliary dilatationOFFSIDES
12Blood creatine phosphokinase increasedOFFSIDES
13Blood sodiumOFFSIDES
14Body TemperatureOFFSIDES
15Bone marrow depressionOFFSIDES
16Bone marrow myelogram abnormalOFFSIDES
17Brain Edema2974563CTD
18BulimiaOFFSIDES
19Cardio-respiratory distressOFFSIDES
20CatatoniaOFFSIDES
21Cell DeathOFFSIDES
22Chemotherapeutic drug level increasedOFFSIDES
23Choking sensationOFFSIDES
24CholangiolitisOFFSIDES
25ColectomyOFFSIDES
26ConfabulationOFFSIDES
27ContractureOFFSIDES
28Creatine urine abnormalOFFSIDES
29Creatinine renal clearance decreasedOFFSIDES
30Cytolytic hepatitisOFFSIDES
31DehydrationOFFSIDES
32Depressed Level of ConsciousnessOFFSIDES
33Dilatation intrahepatic duct acquiredOFFSIDES
34Disruptive, Impulse Control, and Conduct Disorders11449038CTD
35Dissociative AmnesiaOFFSIDES
36Dissociative disorderOFFSIDES
37Drug addictOFFSIDES
38DysuriaOFFSIDES
39ErythemaOFFSIDES
40Gamma-Glutamyltransferase IncreasedOFFSIDES
41Gastrointestinal obstructionOFFSIDES
42General physical health deteriorationOFFSIDES
43Glomerulonephritis12508420CTD
44HELLP SyndromeOFFSIDES
45Heat StrokeOFFSIDES
46HemiplegiaOFFSIDES
47Hepatic necrosisOFFSIDES
48HepatitisOFFSIDES
49HomicideOFFSIDES
50Hyperammonemia2974563CTD
51HyporeflexiaOFFSIDES
52IleectomyOFFSIDES
53Inappropriate affectOFFSIDES
54Incorrect drug administration durationOFFSIDES
55Inflammation12508420CTD
56Initial insomniaOFFSIDES
57Kidney FailureOFFSIDES
58LaparotomyOFFSIDES
59MegacolonOFFSIDES
60OverdoseOFFSIDES
61PallorOFFSIDES
62Pancreatic CystOFFSIDES
63Pancreatic PseudocystOFFSIDES
64PhlebitisOFFSIDES
65PlagiocephalyOFFSIDES
66Pneumococcal sepsisOFFSIDES
67Pre-EclampsiaOFFSIDES
68Psychomotor skills impairedOFFSIDES
69RetrocollisOFFSIDES
70Retroperitoneal fibrosisOFFSIDES
71SchizophreniaOFFSIDES
72Seizures11205735CTD
73Sinus bradycardiaOFFSIDES
74Sleep Wake Disorders11112935CTD
75SoliloquyOFFSIDES
76Splenic InfarctionOFFSIDES
77Sudden deathOFFSIDES
78TalipesOFFSIDES
79Transaminases increasedOFFSIDES
80Ultrasound antenatal screenOFFSIDES
81Urea urine abnormalOFFSIDES
82Urine potassium abnormalOFFSIDES
83Vasculitis12508420CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.